LinkedInFacebook
back to homepage

Session 32

Advanced human liver model systems for translational integrated chemical safety testing strategies

Programme of the Session

  • S32-01
    A 2D & 3D fluorescent toxicity pathway reporter platform for high throughput imaging-based evaluation of hepatotoxicity liabilities

    Bob van de Water
    Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands
  • S32-02
    Combined genome, metabolic and environmental engineering to create more functional hepatocytes from pluripotent stem cells

    Catherine Verfaillie
    Stem Cell Institute, KU Leuven, Leuven, Belgium

  • S32-03
    Application of 3D liver microtissues for assessment of drug-induced liver injury (DILI) and for studying liver steatosis 

    Radina Kostadinova, Fabrice Müller, Tobias Strassfeld, Simon Messner, Monika Kijanska, Wolfgang Moritz, Patrick Guye, David Fluri

    InSphero AG, Zurich, Switzerland

  • S32-04
    Multi-organ on a chip: human physiology-based assessment of liver toxicity

    Eva-Maria Dehne, Tobias Hasenberg, Reyk Horland, Uwe Marx
    TissUse GmbH, Berlin, Germany

Session Abstract

The EU-ToxRisk project develops integrated strategies for human chemical safety assessment using animal free methods. A focus is on systemic repeated dose toxicity with the liver as one of the primary target organs. In EU-ToxRisk we systematically assess the applicability of different liver model systems for hepatotoxicity testing. The vision is to evaluate case study compound series in different cell systems and for each model define the feasibility to predict hepatotoxicity. Both high throughput microscopy, biochemical assessment as well as omics readouts are applied in the different systems. We anticipate to establish a proof-of-concept for tiered testing strategies for hepatotoxicity evaluation. In this symposium we will discuss the applicability domain of the different liver model systems, ranging from high throughput imaging based toxicity pathway reporter liver cell systems, primary human hepatocytes, human iPSC-derived hepatocytes, human liver microtissues and organ on a chip model systems. The application of case study compounds within the EU-ToxRisk project allows us to assess fit-for-purpose clarification for the individual models.   
EUROTOXSETOX

© 2016–2017 GUARANT International